| Literature DB >> 26880905 |
Urmeela Taukoorah1, M Fawzi Mahomoodally1.
Abstract
Aloe vera gel (AVG) is traditionally used in the management of diabetes, obesity, and infectious diseases. The present study aimed to investigate the inhibitory potential of AVG against α-amylase, α-glucosidase, and pancreatic lipase activity in vitro. Enzyme kinetic studies using Michaelis-Menten (K m ) and Lineweaver-Burk equations were used to establish the type of inhibition. The antioxidant capacity of AVG was evaluated for its ferric reducing power, 2-diphenyl-2-picrylhydrazyl hydrate scavenging ability, nitric oxide scavenging power, and xanthine oxidase inhibitory activity. The glucose entrapment ability, antimicrobial activity, and total phenolic, flavonoid, tannin, and anthocyanin content were also determined. AVG showed a significantly higher percentage inhibition (85.56 ± 0.91) of pancreatic lipase compared to Orlistat. AVG was found to increase the Michaelis-Menten constant and decreased the maximal velocity (V max) of lipase, indicating mixed inhibition. AVG considerably inhibits glucose movement across dialysis tubes and was comparable to Arabic gum. AVG was ineffective against the tested microorganisms. Total phenolic and flavonoid contents were 66.06 ± 1.14 (GAE)/mg and 60.95 ± 0.97 (RE)/mg, respectively. AVG also showed interesting antioxidant properties. The biological activity observed in this study tends to validate some of the traditional claims of AVG as a functional food.Entities:
Year: 2016 PMID: 26880905 PMCID: PMC4736367 DOI: 10.1155/2016/3720850
Source DB: PubMed Journal: Adv Pharmacol Sci ISSN: 1687-6334
Figure 1Freshly cut Aloe vera leaves.
Percentage inhibition of AVG against key enzymes.
| Sample | Percentage inhibition | ||
|---|---|---|---|
|
|
| Pancreatic lipase | |
| Acarbose | 96.64 ± 0.10 | 62.70 ± 0.15 | 70.58 ± 0.50 |
|
| −4.88 ± 0.09 | −0.81 ± 0.33 | 85.56 ± 0.91 |
p < 0.05 compared to the control (Acarbose), one-way ANOVA.
Figure 2The Lineweaver-Burk plots in the presence and absence of Aloe vera gel.
Figure 3Glucose movement in vitro.
Glucose content in dialysate.
| Sample | Glucose content in dialysate (mg/mL) | One-way ANOVA ( | ||||
|---|---|---|---|---|---|---|
| 1 hour | 2 hours | 3 hours | 4 hours |
|
| |
| Arabic gum | 0.057 ± 0.005 | 0.136 ± 0.003 | 0.171 ± 0.003 | 0.185 ± 0.001 | 1088.047 | >0.05 |
Glucose diffusion retardation index.
| Sample | Glucose diffusion retardation index | |||
|---|---|---|---|---|
| 1 hour | 2 hours | 3 hours | 4 hours | |
| Arabic gum | 9954 | 9914 | 9943 | 9949 |
|
| 9954 | 9923 | 9945 | 9949 |
Antimicrobial activity of Aloe vera.
| Antimicrobial strains | MIC (mg/mL) | ||||
|---|---|---|---|---|---|
|
| Streptomycin | Chloramphenicol | Ciprofloxacin | Amphotericin | |
|
| — | 0.002 | 0.004 | No growth | — |
|
| — | 0.016 | 0.002 | No growth | — |
|
| — | 0.008 | 0.063 | No growth | — |
|
| — | — | — | — | 0.063 |
|
| — | — | — | — | 0.063 |
Antioxidant activity of Aloe vera.
| Assays | Percentage inhibition | One-way ANOVA | ||
|---|---|---|---|---|
|
| Control |
|
| |
| DPPH free radical scavenging assay | 17.11 ± 1.30 | 81.78 ± 0.24a | 7153.206 | <0.05 |
| NO∙ scavenging assay | 34.88 ± 0.52 | 87.25 ± 0.74b | 9935.925 | <0.05 |
| Xanthine oxidase inhibitory assay | 73.85 ± 2.02 | 85.94 ± 0.11c | 106.801 | <0.05 |
aAscorbic acid (400 μg/mL), bascorbic acid (2 mg/mL), and callopurinol (100 μg/mL).
Phytochemical content of A. vera.
| Assays |
|
|---|---|
| Total phenolic content | 66.06 ± 1.14a |
| Total flavonoid content | 60.95 ± 0.97b |
| Total tannin content | 21.11 ± 1.92c |
| Total anthocyanin content | ND |
a μg gallic acid equivalent (GAE)/mg, b μg rutin equivalent (RE)/mg, and c μg catechin equivalent; ND: not detected.